Predicate |
Object |
contentType |
Comparative Study|Journal Article|Review |
endingPage |
913 |
issn |
1744-8344 1477-9072 |
issueIdentifier |
6 |
pageRange |
903-913 |
publicationName |
Expert Review of Cardiovascular Therapy |
startingPage |
903 |
bibliographicCitation |
Schneider DJ, Aggarwal A. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Expert Rev Cardiovasc Ther. 2004 Nov;2(6):903–13. doi: 10.1586/14779072.2.6.903. PMID: 15500435. |
creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88519c14e7470a104915d16907aff4c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df6734503a0d6597fe88f0e9e6a67adf |
date |
200411 |
identifier |
https://doi.org/10.1586/14779072.2.6.903 https://pubmed.ncbi.nlm.nih.gov/15500435 |
isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/31840 https://portal.issn.org/resource/ISSN/1744-8344 https://portal.issn.org/resource/ISSN/1477-9072 |
language |
English |
source |
https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ |
title |
Development of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit |
discusses |
http://id.nlm.nih.gov/mesh/M0008430 http://id.nlm.nih.gov/mesh/M0028424 http://id.nlm.nih.gov/mesh/M0017012 |
hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D019039Q000037 http://id.nlm.nih.gov/mesh/D003327Q000188 http://id.nlm.nih.gov/mesh/D010975Q000493 http://id.nlm.nih.gov/mesh/D010975Q000627 |
hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D001665 http://id.nlm.nih.gov/mesh/D001682 http://id.nlm.nih.gov/mesh/D012680 http://id.nlm.nih.gov/mesh/D003327Q000175 http://id.nlm.nih.gov/mesh/D016032 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005340Q000187 http://id.nlm.nih.gov/mesh/D008297 |
discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID448812 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60947 |